A new controversial California startup company known as Ambrosia has been selling the blood of young individuals for blood transfusions.
For The Record
Ambrosia recently completed its first clinical trial designed to assess the benefits of the procedure, but it has yet to publish the results. The company is charging a minimum of eight thousand dollars to fill your veins with the blood of young people.
Jesse Karmazin, a startup founder and Stanford Medical School graduate, launched Ambrosia about three years ago. Ambrosia is a startup that fills the veins of older people with the blood from younger donors. The procedure is believed to have an age reversing effect as well as to help rejuvenate the body’s organs.
In 2017, Ambrosia enrolled people in a clinical trial to see the results of injecting the blood of young donors into older individuals. The results of the study have not been made public, but Karmazin told Business Insider in September that they were “really positive”. There is no scientific evidence to suggest that the treatment could help anyone, but because the Food and Drug Administration has approved blood transfusions, Ambrosia has been able to continue their business as an off-label treatment.
The company is now available to the public. Ambrosia recently revamped their website with a list of clinic locations, and are now accepting payments for the procedure through PayPal. The company offers two options: one liter of young blood for $8,000, or two liters for $12,000.
Karmazin, who is not a licensed medical practitioner, told Business Insider in the fall, that he planned to open the first Ambrosia clinic in New York City by the end of the year. Karmazin did not follow through with this plan. Instead, he announced the sites where customers can get the procedure, including Los Angeles; San Francisco; Tampa, Florida; Omaha, Nebraska; and Houston, Texas.
There seems to be significant interest in the procedure. Only a week after launching its first website, the company received about 100 inquires about how to get the treatment, which led to the creation of a waiting list.
The science behind the treatment remains unclear about whether infusions of young blood can help fight aging. Nevertheless, Karmazin is optimistic that blood has a range of benefits. He stated that many of the roughly 150 people who had received the treatment described benefits including renewed focus, better memory and sleep, and improved appearance and muscle tone. It is difficult to quantify these benefits before the study’s findings are made public, but Karmazin remains hopeful that the benefits he said he is seeing are the results of the young-blood transfusions. Does young blood hold the key to a long and healthy life?